| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-138-9-200305060-00006 |
| P698 | PubMed publication ID | 12729424 |
| P50 | author | Hillard M. Lazarus | Q74988477 |
| P2093 | author name string | Drew J Winston | |
| Richard T Maziarz | |||
| Pranatharthi H Chandrasekar | |||
| Gerhard J Leitz | |||
| Jeffrey L Blumer | |||
| Mitchell Goldman | |||
| Mary C Territo | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| fluconazole | Q411478 | ||
| P304 | page(s) | 705-713 | |
| P577 | publication date | 2003-05-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial | |
| P478 | volume | 138 |
| Q52726961 | A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept. |
| Q44849781 | A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan |
| Q44973658 | A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation |
| Q83919477 | A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients |
| Q46788383 | Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation |
| Q36259905 | Advances and challenges in management of invasive mycoses |
| Q43571175 | Adverse drug interactions as a high-risk factor for lethal post-transplant complications in Chinese population |
| Q54394711 | An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. |
| Q40886644 | Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: "real life" evaluation |
| Q28080147 | Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients |
| Q37993110 | Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice |
| Q37816399 | Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients |
| Q37727168 | Antifungal prophylaxis and treatment in patients with hematological malignancies |
| Q37866827 | Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? |
| Q36658236 | Antifungal prophylaxis following reduced-intensity stem cell transplantation |
| Q57746292 | Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy |
| Q35589175 | Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia |
| Q36591360 | Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection |
| Q42217316 | Antimicrobial prophylaxis in hematopoietic stem cell transplantation recipients: 10 years after |
| Q37772501 | Approaches to the early treatment of invasive fungal infection |
| Q33719294 | Aspergillus infections in transplant recipients |
| Q48613970 | Behavior of itraconazole and benzyl alcohol in aqueous solution containing nonionic surfactants. |
| Q56380903 | Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions |
| Q34237335 | Canadian clinical practice guidelines for invasive candidiasis in adults |
| Q37081683 | Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients |
| Q35833407 | Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients |
| Q44703532 | Clinical evaluation of ERCP and naobiliary drainage for biliary fungal infection--a report of five cases of severe combined bacterial and fungal infection of biliary tract |
| Q64930687 | Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: a systematic review and network meta-analysis. |
| Q59308857 | Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation |
| Q37636223 | Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. |
| Q38284455 | Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. |
| Q38284468 | Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. |
| Q44878439 | Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections |
| Q37079099 | Current and future therapeutic options in the management of invasive aspergillosis |
| Q37402524 | Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients |
| Q37151326 | Current options in antifungal pharmacotherapy. |
| Q53584539 | Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation. |
| Q37833638 | Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies |
| Q37650317 | Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. |
| Q45995163 | Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. |
| Q40562962 | Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. |
| Q36111766 | Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada |
| Q85964857 | Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants |
| Q33898397 | Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials |
| Q36714507 | Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies |
| Q90248380 | Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant |
| Q35033597 | Evidence-based guidelines for empirical therapy of neutropenic fever in Korea |
| Q34490092 | Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? |
| Q45168346 | Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials |
| Q37739908 | Fungal infections after hematopoietic stem cell transplantation |
| Q36382582 | Fungal infections in bone marrow transplant recipients |
| Q38178526 | Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. |
| Q28388806 | Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective |
| Q46415258 | Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. |
| Q79686756 | High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation |
| Q34041745 | In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods |
| Q42107363 | In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis |
| Q39195902 | Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. |
| Q53636518 | Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. |
| Q40452785 | Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy. |
| Q58775551 | Invasive Aspergillosis in Children: Update on Current Guidelines |
| Q42119440 | Invasive Candida infections in patients with haematological malignancies and hematopoietic stem cell transplant recipients: current epidemiology and therapeutic options |
| Q46709631 | Invasive aspergillosis and allogeneic hematopoietic stem cell transplantation in children: a 15-year experience |
| Q35616161 | Invasive aspergillosis in patients with hematologic malignancies. |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q44686777 | Invasive fungal infections in patients with hematologic malignancies: the next steps |
| Q41480974 | Invasive fungal infections in pediatric hematopoietic stem cell transplant patients |
| Q35917270 | Itraconazole (Sporanox) in superficial and systemic fungal infections |
| Q44606439 | Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants |
| Q38103889 | Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections |
| Q51551309 | Latest trends in fungal epidemiology inform treatment choices and stewardship initiatives. |
| Q34280580 | Management of Candida species infections in critically ill patients |
| Q37202860 | Management of fungal infections following allogeneic stem cell transplantation |
| Q35675979 | Management of infectious complications in the hematopoietic stem cell transplant recipient |
| Q37810281 | Managing fungal and viral infections in pediatric leukemia |
| Q35026516 | Micafungin in the treatment of invasive candidiasis and invasive aspergillosis |
| Q46688318 | Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection. |
| Q35949528 | Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analys |
| Q36439034 | Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis |
| Q35561985 | New approaches to invasive fungal infections |
| Q38078608 | Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis |
| Q35536063 | Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease. |
| Q35790799 | Novel approaches to antifungal prophylaxis |
| Q46512137 | Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. |
| Q35756513 | Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination |
| Q43756553 | Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q41688288 | Prevention of Invasive Aspergillosis in High-Risk Patients: Universal Versus Preemptive, Targeted Treatment |
| Q38202583 | Prevention of infection in cancer patients |
| Q44968373 | Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles |
| Q88984645 | Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials |
| Q36406975 | Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. |
| Q37657464 | Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question? |
| Q37621550 | Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts |
| Q38222029 | Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. |
| Q37344532 | Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. |
| Q37603180 | Principles and overview of allogeneic hematopoietic stem cell transplantation. |
| Q42415929 | Prophylaxis of invasive fungal diseases in patients with hematologic disorders |
| Q33514002 | Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials |
| Q34450423 | Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation |
| Q35991478 | Recent developments in the management of invasive fungal infections in patients with hematological malignancies. |
| Q38114270 | Recommendations for the management of candidemia in adults in Latin America. Latin America Invasive Mycosis Network. |
| Q40475150 | Reduction in incidence of invasive fungal infection in patients receiving allogeneic stem cell transplantation using combined diagnostic-driven approach and itraconazole oral solution. |
| Q36531721 | Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients |
| Q44905175 | Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation |
| Q37935599 | Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients |
| Q36568458 | Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections |
| Q81086319 | Supportive care |
| Q28083874 | Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients |
| Q44606392 | Systemic antifungal agents |
| Q37119023 | Tailored treatment of invasive fungal infections |
| Q43224589 | The management of febrile neutropenia in the posaconazole era: a new challenge? |
| Q79829816 | The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study |
| Q27009221 | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| Q35680443 | Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease |
| Q34667166 | Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update |
| Q37964703 | Triazole antifungal agents in invasive fungal infections: a comparative review |
| Q38263489 | Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients |
| Q61832641 | Update on invasive fungal infections: the last two years |
| Q37785548 | Updated guidelines for managing fungal diseases in hematology patients |
| Q36364856 | Use of antifungal drugs in hematology |
| Q39196770 | Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation |
| Q33774641 | Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. |
| Q35659502 | Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation |
| Q36774266 | Zygomycosis--current epidemiological aspects |
Search more.